We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

80 hedge funds and large institutions have $41.7M invested in Matinas BioPharma in 2021 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 12

57% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 14

13% more funds holding

Funds holding: 71 → 80 (+9)

0.02% less ownership

Funds ownership: 0.42% → 0.4% (-0.02%)

27% less capital invested

Capital invested by funds: $57.1M → $41.7M (-$15.3M)

Holders
80
Holders Change
+9
Holders Change %
+12.68%
% of All Funds
1.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
22
Reduced
14
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
+$4.81M
2
BlackRock
BlackRock
New York
+$1.25M
3
HF
HRT Financial
New York
+$998K
4
SIG
Sargent Investment Group
Maryland
+$777K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$407K

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$8.77M
2
Renaissance Technologies
Renaissance Technologies
New York
-$1.45M
3
PFMOSF
Philadelphia Financial Management of San Francisco
California
-$1.01M
4
CIBC Private Wealth Group
CIBC Private Wealth Group
Georgia
-$816K
5
Millennium Management
Millennium Management
New York
-$549K
Name Holding Trade Value Shares
Change 		Change in
Stake
LPL Financial
26
LPL Financial
California
$160K +$24.6K +366 +14%
Renaissance Technologies
27
Renaissance Technologies
New York
$147K -$1.45M -21,575 -88%
PAG
28
Private Advisor Group
New Jersey
$143K +$28.6K +427 +19%
State Street
29
State Street
Massachusetts
$142K +$11.1K +166 +7%
Cerity Partners
30
Cerity Partners
New York
$129K +$165K +2,460 New
MA
31
MYDA Advisors
New York
$105K +$134K +2,000 New
LP
32
LMR Partners
United Kingdom
$104K +$133K +1,986 New
WG
33
Winton Group
United Kingdom
$93K -$9.79K -146 -8%
TSS
34
Two Sigma Securities
New York
$86K +$110K +1,639 New
Stifel Financial
35
Stifel Financial
Missouri
$85K +$37.4K +557 +52%
CDH
36
Charles D. Hyman
$84K – – –
Charles Schwab
37
Charles Schwab
California
$83K +$58.1K +866 +123%
TRCT
38
Tower Research Capital (TRC)
New York
$83K +$96.1K +1,432 +968%
MA
39
MONECO Advisors
Connecticut
$53K – – –
JP Morgan Chase
40
JP Morgan Chase
New York
$47K – – –
IFG
41
Investors Financial Group
Minnesota
$47K +$20.1K +300 +50%
Morgan Stanley
42
Morgan Stanley
New York
$42K +$335 +5 +0.6%
CSS
43
Cubist Systematic Strategies
Connecticut
$39K +$49.9K +744 New
Commonwealth Equity Services
44
Commonwealth Equity Services
Massachusetts
$38K +$10.1K +150 +26%
IIA
45
IPG Investment Advisors
California
$34K +$43.5K +648 New
AWA
46
Arete Wealth Advisors
Illinois
$32K – – –
CWM
47
CCG Wealth Management
California
$32K – – –
Millennium Management
48
Millennium Management
New York
$31K -$549K -8,191 -93%
MS
49
Maven Securities
Jersey
$30K +$36.4K +543 New
Jane Street
50
Jane Street
New York
$25K -$2.42K -36 -7%
1
2
3 4

MTNB Hedge Fund Activity: Q1 2021 in Review

80 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2021, worth a combined $41.7M — down 27% from $57.1M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new MTNB positions and 12 closed out — a net gain of 10 holders — while 22 added to existing stakes and 14 trimmed.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $4.81M. The largest seller was Vivo Capital, exiting entirely with an estimated $8.77M sold.

  • 80 institutional investors held Matinas BioPharma (MTNB) as of Q1 2021, up from 71 in Q4 2020.
  • Funds reported $41.7M of Matinas BioPharma stock for Q1 2021, down 27% quarter-over-quarter.
  • 22 funds opened new Matinas BioPharma positions in Q1 2021 and 12 closed out, a net change of +10 holders.
  • The largest Matinas BioPharma buyer in Q1 2021 was Anson Funds Management, an estimated $4.81M added.
  • The largest Matinas BioPharma seller in Q1 2021 was Vivo Capital, an estimated $8.77M sold.

Based on aggregated 13F filings for Q1 2021.